{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:58:10Z","timestamp":1790794690177,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25ek0109701"],"award-info":[{"award-number":["25ek0109701"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Next-generation sequencing has increased the sensitivity of pathogenic variant (PV) detection and enabled the quantitative assessment of variant allele fractions (VAFs) in clinical cancer genetics. However, these advances have exposed the limitations of equating molecular detection with a definitive germline diagnosis. The most clinically consequential example is TP53: in leukocyte-derived DNA, a detected TP53 PV may represent constitutional germline heterozygosity, postzygotic constitutional mosaicism, or blood-limited clonal hematopoiesis, including acquired clonal expansion to high VAF. Rarely, a detected signal may reflect circulating tumor cell\u2013related tumor-in-normal contamination. Separately, an apparent variant signal may reflect a technical artifact rather than a true biological finding. Accurate origin attribution is essential because Li\u2013Fraumeni syndrome (LFS) confers a high lifetime risk of multiple cancers, and confirmed constitutional TP53 PVs have major implications for lifelong surveillance, cancer treatment, reproductive counseling, and cascade testing. Misattribution may lead to either overdiagnosis with unnecessary interventions or under-recognition of clinically significant constitutional mosaicism. This interpretive challenge now extends beyond hereditary cancer clinics. In tumor-only cancer genomic profiling (CGP) or liquid biopsy, a TP53 PV does not by itself establish germline origin but may prompt germline follow-up when allele fraction, tumor context, and clinical features are compatible. This issue is particularly relevant in Japan, where germline TP53 testing for suspected LFS has not been routinely available under the national health insurance system and where CGP has become an important entry point to presumed germline or uncertain-origin findings. This review proposes an origin-aware, three-layer framework comprising variant pathogenicity assessment, origin attribution, and clinical actionability. The goal is structured management of uncertainty to support proportionate surveillance, cascade testing, and shared decision-making.<\/jats:p>","DOI":"10.1093\/jjco\/hyag158","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:21:39Z","timestamp":1790594499000},"source":"Crossref","is-referenced-by-count":0,"title":["Interpreting\n                    <i>TP53<\/i>\n                    pathogenic variants in germline testing and cancer genomics: pathogenicity, origin, and clinical actionability"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4150-7938","authenticated-orcid":false,"given":"Issei","family":"Imoto","sequence":"first","affiliation":[{"name":"Aichi Cancer Center Research Institute , 1-1 Kanokoden, Chikusaku, Nagoya, Aichi 464-8681 ,","place":["Japan"]},{"name":"Risk Assessment Unit, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobue","family":"Takaiso","sequence":"additional","affiliation":[{"name":"Risk Assessment Unit, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-9158","authenticated-orcid":false,"given":"Akiyo","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Risk Assessment Unit, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]},{"name":"Department of Breast Oncology, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026093014281982600_ref1","author":"Schneider","year":"1993\u20132026"},{"key":"2026093014281982600_ref2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study","volume":"12","author":"Villani","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026093014281982600_ref3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026093014281982600_ref4","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026093014281982600_ref5","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"2026093014281982600_ref6","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-24-3301","article-title":"Update on cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"31","author":"Achatz","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026093014281982600_ref7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/gim.2017.196","article-title":"Somatic TP53 variants frequently confound germ-line testing results","volume":"20","author":"Weitzel","year":"2018","journal-title":"Genet Med"},{"key":"2026093014281982600_ref8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13058-019-1193-1","article-title":"Li-Fraumeni syndrome: not a straightforward diagnosis anymore\u2014the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis","volume":"21","author":"Batalini","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026093014281982600_ref9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jmoldx.2019.12.003","article-title":"Apparently heterozygous TP53 pathogenic variants may be blood limited in patients undergoing hereditary cancer panel testing","volume":"22","author":"Mester","year":"2020","journal-title":"J Mol Diagn"},{"key":"2026093014281982600_ref10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2026093014281982600_ref11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13073-025-01536-3","article-title":"A quantitative, Bayesian-informed approach to gene-specific variant classification: updated expert panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome","volume":"17","author":"Fortuno","year":"2025","journal-title":"Genome Med"},{"key":"2026093014281982600_ref12","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2026093014281982600_ref13","author":"Japanese Association of Medical Sciences"},{"key":"2026093014281982600_ref14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jmoldx.2016.01.002","article-title":"Detection and quantification of mosaic mutations in disease genes by next-generation sequencing","volume":"18","author":"Qin","year":"2016","journal-title":"J Mol Diagn"},{"key":"2026093014281982600_ref15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41586-025-09096-7","article-title":"The somatic mosaicism across human tissues network","volume":"643","author":"Coorens","year":"2025","journal-title":"Nature"},{"key":"2026093014281982600_ref16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrg3424","article-title":"A genomic view of mosaicism and human disease","volume":"14","author":"Biesecker","year":"2013","journal-title":"Nat Rev Genet"},{"key":"2026093014281982600_ref17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/genes5041064","article-title":"Somatic mosaicism in the human genome","volume":"5","author":"Freed","year":"2014","journal-title":"Genes (Basel)"},{"key":"2026093014281982600_ref18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00438-015-1130-7","article-title":"Unrevealed mosaicism in the next-generation sequencing era","volume":"291","author":"Gajecka","year":"2016","journal-title":"Mol Gen Genomics"},{"key":"2026093014281982600_ref19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41583-022-00572-x","article-title":"Genetic mosaicism in the human brain: from lineage tracing to neuropsychiatric disorders","volume":"23","author":"Bizzotto","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"2026093014281982600_ref20","author":"NHS England Genomics Education Programme Mosaicism [Internet]"},{"key":"2026093014281982600_ref21","author":"NHS England Genomics Education Programme"},{"key":"2026093014281982600_ref22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"2026093014281982600_ref23","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"2026093014281982600_ref24","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2026093014281982600_ref25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.stem.2022.05.006","article-title":"Clonal hematopoiesis: mutation-specific adaptation to environmental change","volume":"29","author":"Florez","year":"2022","journal-title":"Cell Stem Cell"},{"key":"2026093014281982600_ref26","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-18-1201","article-title":"Identification of clonal Hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays","volume":"24","author":"Coombs","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026093014281982600_ref27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.18.00331","article-title":"Managing clonal Hematopoiesis in patients with solid Tumors","volume":"37","author":"Bolton","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026093014281982600_ref28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cancergen.2017.01.002","article-title":"Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel","volume":"211","author":"Coffee","year":"2017","journal-title":"Cancer Genet"},{"key":"2026093014281982600_ref29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/humu.23910","article-title":"A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically","volume":"41","author":"Coffee","year":"2020","journal-title":"Hum Mutat"},{"key":"2026093014281982600_ref30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cancergen.2019.04.005","article-title":"Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing","volume":"235-236","author":"Slavin","year":"2019","journal-title":"Cancer Genet"},{"key":"2026093014281982600_ref31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1200\/PO.19.00279","article-title":"Challenges in interpreting TP53 pathogenic variants with a low minor allele frequency in germline genetic testing: a case report of a patient with mosaic Li-Fraumeni syndrome","volume":"4","author":"Peacock","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2026093014281982600_ref32","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1158\/1055-9965.EPI-21-1296","article-title":"Clonal hematopoiesis and mosaicism revealed by a multi-tissue analysis of constitutional TP53 status","volume":"31","author":"Castillo","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026093014281982600_ref33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cancergen.2022.07.004","article-title":"Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels","volume":"266-267","author":"Sutcliffe","year":"2022","journal-title":"Cancer Genet"},{"key":"2026093014281982600_ref34","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1158\/1078-0432.CCR-24-4105","article-title":"Low allele frequency variants identified on germline multi-gene panel testing for cancer predisposition can suggest the presence of constitutional mosaicism","volume":"31","author":"Rodriguez-Hernandez","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026093014281982600_ref35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13073-025-01429-5","article-title":"TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate","volume":"17","author":"Rofes","year":"2025","journal-title":"Genome Med"},{"key":"2026093014281982600_ref36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/jgc4.1789","article-title":"Interpretation of ambiguous TP53 test results: mosaicism, clonal hematopoiesis, and variants of uncertain significance","volume":"33","author":"Berry","year":"2024","journal-title":"J Genet Couns"},{"key":"2026093014281982600_ref37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cancergen.2024.04.002","article-title":"Clinical management of TP53 mosaic variants found on germline genetic testing","volume":"284-285","author":"Ward","year":"2024","journal-title":"Cancer Genet"},{"key":"2026093014281982600_ref38","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s10147-021-02011-w","article-title":"Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1","volume":"26","author":"Kumamoto","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2026093014281982600_ref39","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00291","article-title":"Precision oncology and the universal health coverage system in Japan","volume":"3","author":"Ebi","year":"2019","journal-title":"JCO precis Oncologia"},{"key":"2026093014281982600_ref40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/jmg-2025-110947","article-title":"Proposed framework for triage of putative germline variants detected via tumour genomic testing in UK oncology practice","volume":"62","author":"McVeigh","year":"2025","journal-title":"J Med Genet"},{"key":"2026093014281982600_ref41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41698-023-00429-1","article-title":"Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing","volume":"7","author":"Tung","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026093014281982600_ref42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s10038-023-01133-5","article-title":"Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: a retrospective analysis at a single facility","volume":"68","author":"Kawamura","year":"2023","journal-title":"J Hum Genet"},{"key":"2026093014281982600_ref43","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"key":"2026093014281982600_ref44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s10038-024-01294-x","article-title":"Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsy","volume":"70","author":"Shimada","year":"2025","journal-title":"J Hum Genet"},{"key":"2026093014281982600_ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s10038-025-01389-z","article-title":"Germline pathogenic variants detected by GenMineTOP: insight from a nationwide tumor\/normal paired comprehensive genomic profiling test, in Japan","volume":"71","author":"Habano","year":"2026","journal-title":"J Hum Genet"},{"key":"2026093014281982600_ref46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40246-017-0118-2","article-title":"Evaluating somatic tumor mutation detection without matched normal samples","volume":"11","author":"Teer","year":"2017","journal-title":"Hum Genomics"},{"key":"2026093014281982600_ref47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s13058-014-0445-3","article-title":"TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients","volume":"16","author":"Fernandez","year":"2014","journal-title":"Breast Cancer Res"},{"key":"2026093014281982600_ref48","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/jjco\/hyaf011","article-title":"A case of Li-Fraumeni syndrome caused by a 3.6 kb deletion in the TP53 gene suggested by additional data from the NCC Oncopanel","volume":"55","author":"Souma","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026093014281982600_ref49","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jjco\/hyac046","article-title":"Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system","volume":"52","author":"Higashigawa","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2026093014281982600_ref50","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/1078-0432.CCR-25-2985","article-title":"Germline pathogenic variant prediction model for tumor-only sequencing based on Japanese clinicogenomic database","volume":"32","author":"Ikegami","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026093014281982600_ref51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/jjco\/hyag022","article-title":"Uptake of cascade tests in relatives of patients undergoing cancer precision medicine in Japan","volume":"56","author":"Matsubayashi","year":"2026","journal-title":"Jpn J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag158\/71531325\/hyag158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag158\/71531325\/hyag158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:28:26Z","timestamp":1790792906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag158\/8855617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag158","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"hyag158"}}